The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

Within 24 hours of hospitalization, participants were randomly assigned to dapagliflozin 10 mg once daily or structured usual care with protocolized diuretic titration until day 5 or hospital ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

Patients were randomized (1:1:1) to oral dapagliflozin 5 mg or 10 mg once daily or matched placebo, plus insulin. For safety analyses, 833 patients were randomized to groups (dapagliflozin 5 mg n ...

Within 24 hours of hospital presentation, patients were randomly assigned in a 1:1 ratio to oral dapagliflozin 10 mg once daily or structured usual care until day 5 or hospital discharge.

Trial investigators randomized 6,263 patients with an LVEF over 40%, evidence of structural heart disease, and elevated natriuretic peptides to dapagliflozin 10 mg once daily or placebo on top of ...

ORLANDO, Florida — The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) significantly slowed progression of renal dysfunction or death from cardiovascular causes among ...

They randomized 43 patients (mean age 67 years; 66% women) with HFpEF (LVEF ≥ 50%), NYHA class II/III symptoms, and an elevated PCWP, with 38 ultimately receiving treatment with either placebo or ...